NEW
YORK, June 1, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that Robert Barrow, Chief Executive
Officer and Director, will participate in the Jefferies Global
Healthcare Conference, to be held in New
York, NY from June 8-10,
2022.
Jefferies Global Healthcare Conference
Format:
In-person presentation and scheduled one-on-one investor
meetings
Presentation Date: Friday, June 10,
2022
Time: 12:45 p.m. ET
Webcast Link: https://wsw.com/webcast/jeff240/mnmd/1841100
A replay of the webcast will be available in the "News &
Media" section of MindMed's website for 90 days following each of
the presentations.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. Our mission is
to be the global leader in the development and delivery of
treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-jefferies-global-healthcare-conference-301558892.html
SOURCE Mind Medicine (MindMed) Inc.